fda glp-1 warning news november 2025 The growing availability of compounded weight-loss drugs has prompted warnings from doctors and the U.S. Food and Drug Administration. https://www.abc27.com/national/compounded-glp-1 -drugs-creating-concern-among-doctors-and-fda/?utm_medium FDA issued 25 warning letters

Glucagon-like peptide-1 (GLP-1) in the integration of neural and endocrine responses to stress

Making these medications more accessible gives many patients an opportunity they may not have had before. How GLP-1 Medications Work GLP-1 medications work by helping regulate appetite and slowing stomach emptying, allowing patients to feel full longer and eat less

The size for the obesity GLP-1 market is projected to reach USD 65,364 million by 2035

But many people dislike needles, which is where oral options become attractive

Retatrutide is not approved in the UK, so there is no licensed 12mg dose for patients

Some more than others experience structural barriers to food, nutrition and lifestyle skills